M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Retifanlimab (INCMGA00012) and Telotristat Ethyl for the Treatment of Advanced Neuroendocrine Tumors and Carcinoid Syndrome

Phase 2

Withdrawn

Conditions: Advanced Neuroendocrine Neoplasm
Carcinoid Syndrome

Interventions: Biological: Retifanlimab
Drug: Telotristat Ethyl

First Posted Date: 2021-03-02

Last Posted Date: 2021-09-29

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT04776876

Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Phase 1

Recruiting

Conditions: Acute Myeloid Leukemia
Recurrent Acute Myeloid Leukemia
Refractory Acute Myeloid Leukemia

Interventions: Drug: Decitabine and Cedazuridine
Drug: Ivosidenib
Drug: Enasidenib
Drug: Venetoclax

First Posted Date: 2021-03-01

Last Posted Date: 2024-06-04

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 84

Registration Number: NCT04774393

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Effect of Digital Health Coaching Program on Self-efficacy and Patient Reported Outcomes of Patients With Newly Diagnosed Acute Myeloid Leukemia or Chronic Lymphocytic Leukemia

Not Applicable

Completed

Conditions: Chronic Lymphocytic Leukemia
Acute Myeloid Leukemia

Interventions: Other: Educational Intervention
Other: Supportive Care
Other: Questionnaire Administration

First Posted Date: 2021-03-01

Last Posted Date: 2023-09-18

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 157

Registration Number: NCT04774744

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors

Phase 2

Recruiting

Conditions: Anatomic Stage IV Breast Cancer AJCC V8
Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC V8
Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC V8
Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC V8
Locally Advanced Malignant Solid Neoplasm
Locally Advanced Melanoma
Locally Advanced Primary Malignant Central Nervous System Neoplasm
Locally Advanced Sarcoma
Metastatic Malignant Solid Neoplasm
Metastatic Melanoma

Interventions: Drug: Avapritinib

First Posted Date: 2021-02-25

Last Posted Date: 2024-10-24

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 50

Registration Number: NCT04771520

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Serial Advanced Magnetic Resonance Imaging Scan for Guidance of Personalized Adaptive Radiotherapy for High Grade Glioma

Recruiting

Conditions: Malignant Glioma

Interventions: Procedure: Magnetic Resonance Imaging
Other: Neurocognitive Assessment
Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2021-02-25

Last Posted Date: 2024-03-22

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 80

Registration Number: NCT04771806

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Acalabrutinib and Rituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma

Phase 2

Active, not recruiting

Conditions: Mantle Cell Lymphoma

Interventions: Drug: Acalabrutinib
Biological: Rituximab

First Posted Date: 2021-02-21

Last Posted Date: 2024-11-27

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 53

Registration Number: NCT04765111

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer

Phase 2

Active, not recruiting

Conditions: Malignant Thyroid Gland Neoplasm
Poorly Differentiated Thyroid Gland Carcinoma
Thyroid Gland Anaplastic Carcinoma
Thyroid Gland Papillary Carcinoma
Thyroid Gland Squamous Cell Carcinoma
Recurrent Thyroid Gland Carcinoma
Thyroid Gland Medullary Carcinoma

Interventions: Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Drug: Selpercatinib
Procedure: Therapeutic Conventional Surgery

First Posted Date: 2021-02-18

Last Posted Date: 2024-11-04

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 30

Registration Number: NCT04759911

Locations: 🇺🇸
University of Michigan Health Systems, Ann Arbor, Michigan, United States
🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Immunotherapy (NHS-IL12 & Bintrafusp Alfa) and Radiation Therapy for the Treatment of Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer, the REINA Trial

Phase 1

Withdrawn

Conditions: Metastatic Breast Carcinoma
Prognostic Stage IV Breast Cancer AJCC v8
Anatomic Stage IV Breast Cancer AJCC v8
Hormone Receptor Positive Breast Adenocarcinoma
Metastatic HER2 Negative Breast Adenocarcinoma

Interventions: Drug: Bintrafusp Alfa
Biological: Immunocytokine NHS-IL12
Radiation: Radiation Therapy

First Posted Date: 2021-02-16

Last Posted Date: 2023-12-27

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT04756505

Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer

Phase 2

Active, not recruiting

Conditions: Metastatic Prostate Small Cell Neuroendocrine Carcinoma
Castration-Resistant Prostate Carcinoma Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents
Metastatic Malignant Neoplasm in the Bone
Stage IVB Prostate Cancer AJCC v8
Metastatic Prostate Adenocarcinoma
Castration-Resistant Prostate Carcinoma
Stage IV Prostate Cancer AJCC v8
Stage IVA Prostate Cancer AJCC v8

Interventions: Procedure: Biopsy
Procedure: Biospecimen Collection
Drug: Erdafitinib

First Posted Date: 2021-02-15

Last Posted Date: 2024-11-25

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 11

Registration Number: NCT04754425

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Culturally Based Brief Expressive Writing Intervention for the Improvement of Health in Chinese Immigrant Stage 0-III Breast Cancer Survivors, Writing to Heal Study

Not Applicable

Recruiting

Conditions: Anatomic Stage IIB Breast Cancer AJCC v8
Prognostic Stage IA Breast Cancer AJCC v8
Prognostic Stage II Breast Cancer AJCC v8
Prognostic Stage IIIA Breast Cancer AJCC v8
Anatomic Stage IIA Breast Cancer AJCC v8
Anatomic Stage III Breast Cancer AJCC v8
Anatomic Stage IIIB Breast Cancer AJCC v8
Prognostic Stage IB Breast Cancer AJCC v8
Prognostic Stage IIA Breast Cancer AJCC v8
Prognostic Stage III Breast Cancer AJCC v8

Interventions: Other: Behavioral, Psychological or Informational Intervention
Other: Best Practice
Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2021-02-15

Last Posted Date: 2024-11-12

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 240

Registration Number: NCT04754412

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Home Terms & Conditions Privacy Policy